Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 53

2.
3.
5.

2050: Ending the odyssey of the great white plague. Part of a series on Pediatric Pharmacology, guest edited by Gianvincenzo Zuccotti, Emilio Clementi, and Massimo Molteni.

Jassal MS, Aldrovandi GM.

Pharmacol Res. 2011 Sep;64(3):176-9. doi: 10.1016/j.phrs.2011.03.019. Epub 2011 Apr 20.

PMID:
21540112
6.

The development of medicines for children. Part of a series on Pediatric Pharmacology, guest edited by Gianvincenzo Zuccotti, Emilio Clementi, and Massimo Molteni.

Rocchi F, Tomasi P.

Pharmacol Res. 2011 Sep;64(3):169-75. doi: 10.1016/j.phrs.2011.01.016. Epub 2011 Mar 3. Review.

PMID:
21376810
7.

Genes and beans: pharmacogenomics of renal transplant.

Murray B, Hawes E, Lee RA, Watson R, Roederer MW.

Pharmacogenomics. 2013 May;14(7):783-98. doi: 10.2217/pgs.13.68. Review.

PMID:
23651025
8.

Risk factors for and management of post-transplantation cardiovascular disease.

Fellström B.

BioDrugs. 2001;15(4):261-78. Review.

PMID:
11437691
9.

Therapeutics in pediatric diabetes: insulin and non-insulin approaches. Part of a series on Pediatric Pharmacology, guest edited by Gianvincenzo Zuccotti, Emilio Clementi, and Massimo Molteni.

Kim J, Kim SM, Nguyen HC, Redondo MJ.

Pharmacol Res. 2012 Jan;65(1):1-4. doi: 10.1016/j.phrs.2011.08.011. Epub 2011 Sep 10. Review.

PMID:
21930210
10.

The Bergamo Kidney Transplant Program.

Perico N, Cravedi P, Ruggenenti P, Gotti E, Rota G, Locatelli G, Gambara V, Perna A, Rota S, Remuzzi G.

Clin Transpl. 2005:85-100.

PMID:
17424727
11.

Pharmacogenetics in immunosuppressants: impact on dose requirement of calcineurin inhibitors in renal and liver pediatric transplant recipients.

Quteineh L, Verstuyft C.

Curr Opin Organ Transplant. 2010 Oct;15(5):601-7. doi: 10.1097/MOT.0b013e32833de1d0. Review.

PMID:
20720493
12.

Projecting long-term graft and patient survival after transplantation.

Levy AR, Briggs AH, Johnston K, MacLean JR, Yuan Y, L'Italien GJ, Kalsekar A, Schnitzler MA.

Value Health. 2014 Mar;17(2):254-60. doi: 10.1016/j.jval.2014.01.001.

13.

Challenges in pediatric transplantation: the impact of chronic kidney disease and cardiovascular risk factors on long-term outcomes and recommended management strategies.

Filler G.

Pediatr Transplant. 2011 Feb;15(1):25-31. doi: 10.1111/j.1399-3046.2010.01439.x. Epub 2010 Dec 13. Review.

PMID:
21155958
14.
15.

Review of immunosuppressive usage in pancreas transplantation.

Stratta RJ.

Clin Transplant. 1999 Feb;13(1 Pt 1):1-12. Review.

PMID:
10081628
16.

Current progress in pharmacogenetics and individualized immunosuppressive drug dosing in organ transplantation.

Ware N, MacPhee IA.

Curr Opin Mol Ther. 2010 Jun;12(3):270-83. Review.

PMID:
20521216
17.

Improving long-term renal transplant outcomes with tacrolimus: speculation vs evidence.

First MR.

Nephrol Dial Transplant. 2004 Dec;19 Suppl 6:vi17-vi22. Review.

PMID:
15575022
18.

Immunosuppression in live-related donor renal transplantation.

Iman A, Rao M, Juneja R, Jacob CK.

Natl Med J India. 2001 Mar-Apr;14(2):75-80.

PMID:
11396322
19.

What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients.

Jain A, Reyes J, Kashyap R, Rohal S, Abu-Elmagd K, Starzl T, Fung J.

Ann Surg. 1999 Sep;230(3):441-8; discussion 448-9.

20.

Supplemental Content

Support Center